• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Apr 27. 2018
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
Read more
Download
Apr 20. 2018
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more
Download
Apr 19. 2018
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
Read more
Download
Apr 18. 2018
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
Read more
Download
Apr 17. 2018
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
Read more
Download
Apr 09. 2018
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
Read more
Download
Mar 06. 2018
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
Read more
Download
Mar 01. 2018
Basilea names Adesh Kaul as new member of its Management Committee
Read more
Download
Feb 27. 2018
Basilea reports significantly improved financial results in 2017
Read more
Download
Feb 23. 2018
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Read more
Download
  • previous
  • 1
  • …
  • 19
  • 20
  • 21
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil